ASCO 2023 | KEYNOTE-B61: first-line lenvatinib + pembrolizumab in non-clear cell RCC

Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of the the Phase II KEYNOTE-B61 (NCT04704219), which explored the use of lenvatinib plus pembrolizumab as a first-line treatment for advanced non-clear cell renal cell carcinoma (RCC). The study showed promising antitumor activity in a cohort of 158 patients with different non-clear cell RCC histologies, with an objective response rate (ORR) of 49% and a disease control rate (DCR) of 82%. The combination therapy demonstrated favorable outcomes and safety profiles, supporting its use as a first-line treatment option for non-clear cell RCC patients, regardless of histology. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.